Drug duo aims to tackle high blood pressure in obesity
NCT ID NCT07678151
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether combining two medications, empagliflozin and finerenone, can lower blood pressure in adults with obesity and stage 1 hypertension. Participants take the drugs or a placebo daily for 12 weeks. The trial also measures effects on kidney function, inflammation, blood sugar, weight, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin and finerenone
What this could lead to
If successful, this combination could offer a new treatment option for people with obesity and high blood pressure, potentially providing better heart and kidney protection than current therapies.
What could go wrong
This is a 12-week trial with 260 participants, so results are preliminary. The combination may cause side effects like high potassium, kidney injury, low blood pressure, or low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ruyang County People's Hospital
Luoyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact